Payment overview · 2025
General Payments
$547.87
32 reported records · 14 companies
Healthcare provider profile · identity verified
Tammy S. Saylor, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · GRAY, KY · NPI 1821439746
Verified facts
What the public records show
CMS Open Payments records show Tammy S. Saylor, APRN received $547.87 in general payments during 2025 across 32 reported records.
ABBVIE INC. accounted for 39.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $213.58 | 39.0% | 14 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $78.38 | 14.3% | 4 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $45.13 | 8.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $35.43 | 6.5% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $24.61 | 4.5% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $22.13 | 4.0% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $20.95 | 3.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.14 | 3.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.13 | 2.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.39 | 2.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.34 | 2.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.20 | 2.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.81 | 2.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.65 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $547.87 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $157.32 | 9 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $78.38 | 4 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $45.13 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $40.28 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $40.28 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $35.43 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $20.95 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $15.98 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.98 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 92 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 49 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 80 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 340 | 46 |
| Lisinopril | Lisinopril | 332 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 329 | 50 |
| Omeprazole | Omeprazole | 250 | 34 |
| Atorvastatin Calcium | Atorvastatin Calcium | 214 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 187 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 175 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 164 | 23 |
| Metformin Hcl | Metformin Hcl | 159 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 123 | 11 |
| Naloxone Hcl | Naloxone Hcl | 121 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 17 |
| Ibuprofen | Ibuprofen | 112 | 20 |
| Meloxicam | Meloxicam | 108 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 103 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 22 |
| Montelukast Sodium | Montelukast Sodium | 95 | 18 |
| Jardiance | Empagliflozin | 92 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 91 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 89 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 13 |
| Clonazepam | Clonazepam | 82 | 14 |
| Furosemide | Furosemide | 81 | suppressed |
| Ozempic | Semaglutide | 80 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 78 | 12 |
| Ondansetron Odt | Ondansetron | 77 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 14 |
| Trazodone Hcl | Trazodone Hcl | 76 | suppressed |
| Alprazolam | Alprazolam | 73 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 73 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 72 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | suppressed |
| Prednisone | Prednisone | 68 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 66 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 64 | suppressed |
| Potassium Chloride | Potassium Chloride | 63 | suppressed |
| Simvastatin | Simvastatin | 63 | suppressed |
| Carvedilol | Carvedilol | 62 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 55 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 54 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | suppressed |
| Methylprednisolone | Methylprednisolone | 51 | 34 |
| Linzess | Linaclotide | 49 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 47 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 45 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | suppressed |
| Losartan Potassium | Losartan Potassium | 43 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Fluconazole | Fluconazole | 40 | 20 |
| Fenofibrate | Fenofibrate | 39 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Estradiol | Estradiol | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Methocarbamol | Methocarbamol | 35 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Naproxen | Naproxen | 35 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 16 |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Famotidine | Famotidine | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Nabumetone | Nabumetone | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Nystatin | Nystatin | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 18 |
| Atenolol | Atenolol | 26 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 26 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Azithromycin | Azithromycin | 22 | 17 |
| Cefdinir | Cefdinir | 22 | 17 |
| Lorazepam | Lorazepam | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Nyamyc | Nystatin | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Oxaprozin | Oxaprozin | 12 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Glipizide Xl | Glipizide | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $547.87 · 32 records | ABBVIE INC. | ACCRUFER, CAPLYTA, CREON, CRYSVITA, Cologuard Collection Kit, IBSRELA, JARDIANCE, Kerendia, LINZESS, NURTEC ODT, Ohtuvayre, Ozempic, QULIPTA, Rybelsus, SPRAVATO, UBRELVY, VOQUEZNA, VRAYLAR, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error